SCHEMBL1031985

SCHEMBL1031985

N#Cc1ccc2c(c1)CCC2=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.62
PGR P06401 2/20 0.54
CASP1 P29466 1/20 0.53
CASP7 P55210 1/20 0.53
HSD17B10 Q99714 1/20 0.53
MAOA P21397 3/20 0.50
MAOB P27338 3/20 0.50
HSD17B1 P14061 2/20 0.47
DRD2 P14416 2/20 0.44
DRD3 P35462 2/20 0.44
CYP19A1 P11511 2/20 0.44
CYP11B1 P15538 2/20 0.44
CYP11B2 P19099 2/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
PNMT P11086 1/20 0.44
MIF P14174 1/20 0.44
SLC11A2 P49281 1/20 0.43
ACACB O00763 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29741348 1.00 GRM5 (0.62) GRM5PGRCASP1CASP7HSD17B10
SCHEMBL29649348 0.89 GRM5 (0.64) GRM5PGRCASP1CASP7HSD17B10
SCHEMBL1091324 0.89 GRM5 (0.64) GRM5PGRCASP1CASP7HSD17B10
SCHEMBL12063336 0.86 MIF (0.52) GRM5PGRMAOAMAOBDRD2
SCHEMBL4430144 0.86 HSD17B1 (0.63) GRM5PGRCASP1CASP7HSD17B10
SCHEMBL27913249 0.86 DRD2 (0.52) GRM5MAOAMAOBDRD2DRD3
SCHEMBL435225 0.85 PBRM1 (0.53) GRM5PGRCASP1CASP7HSD17B10
SCHEMBL30989980 0.85 PBRM1 (0.53) GRM5PGRCASP1CASP7HSD17B10
SCHEMBL385683 0.82 MAOB (0.59) GRM5PGRCASP1CASP7HSD17B10
SCHEMBL4423216 0.82 PGR (0.56) GRM5PGRMAOAMAOBHSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4126835-B1 INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR JANSSEN PHARMACEUTICA NV (BE) 2026-02-18 EP disclosed
US-12516038-B2 Inhibitors of antigen presentation by HLA-DR JANSSEN PHARMACEUTICA NV (BE) 2026-01-06 US disclosed
EP-4380932-B1 PROCESS FOR PREPARING AFICAMTEN CYTOKINETICS INC (US) 2025-11-26 EP disclosed
CN-120699008-A Preparation method of AFICAMTEN 上海博悦生物科技有限公司 2025-09-26 CN disclosed
CN-120535511-A Preparation method of AFICAMTEN 上海博悦生物科技有限公司 2025-08-26 CN disclosed
US-12247024-B2 Process for preparing aficamten CYTOKINETICS, INC. (US) 2025-03-11 US disclosed
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2025-02-20 US disclosed
EP-4491622-A2 CARDIAC SARCOMERE INHIBITORS Cytokinetics, Inc. (US) 2025-01-15 EP disclosed
US-12187712-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2025-01-07 US disclosed
EP-3740481-B9 DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2024-10-23 EP disclosed
WO-2000051602-A1 UTILIZATION OF POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS IN THE PRODUCTION OF MEDICAMENTS FOR PROPHYLAXIS OR TREATMENT OF OBESITY AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-09-08 WO disclosed
WO-2000051995-A1 POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENT CONTAINING SAID COMPOUNDS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-09-08 WO disclosed
US-6090833-A EATING DISORDERS; ANTIDIABETIC AGENT AVENTIS PHARMA DEUTSCHAND GMBH (DE) 2000-07-18 US disclosed
WO-2000018749-A1 INDENO-, NAPHTO- AND BENZOCYCLOHEPTA DIHYDROTHIAZOLE DERIVATIVES, THE PRODUCTION THEREOF AND THEIR USE AS ANORECTIC MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-04-06 WO disclosed
WO-2000004006-A1 POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-01-27 WO disclosed
EP-0752991-B1 IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN-4-ONES ANTAGONISTS OF AMPA AND NMDA RECEPTORS RHONE POULENC RORER SA (FR) 1999-05-26 EP disclosed
US-5789406-A Indeno 1,2-E!pyrazine-4-ones, their preparation and the medicaments containing them RHONE-POULENC RORER S.A. (FR) 1998-08-04 US disclosed
EP-0752991-A1 INDENO[1,2-e]PYRAZINE-4-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME Aventis Pharma S.A. (FR) 1997-01-15 EP disclosed
WO-1995026349-A1 INDENO[1,2-e]PYRAZINE-4-ONES, PREPARATION THEREOF AND DRUGS CONTAINING SAME RHONE-POULENC RORER S.A. (FR) 1995-10-05 WO disclosed
US-5180741-A Insecticides ROUSSEL UCLAF (FR) 1993-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187712-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 GRM5 4248/4885PGR 4670/4885CASP1 2759/4885
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 GRM5 4207/4885PGR 4568/4885CASP1 3124/4885
US-12247024-B2 Process for preparing aficamten INMT, PNMT, NNMT GRM5 701/4885PGR 4468/4885CASP1 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.